

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	dupilumab
Brand Name	Dupixent™
Dosage Form(s)	150 mg / mL subcutaneous injection
Manufacturer	Sanofi-Aventis Canada Inc.
Submission Type	New Submission
Use Reviewed	Moderate to severe atopic dermatitis
Common Drug Review (CDR)	Yes, CDR recommended: Do Not Reimburse . Visit the CDR website for more details: www.cadth.ca/sites/default/files/cdr/complete/SR0533_cdr_complete_Dupixent_July_9_2018.pdf
Provincial Review	Dupilumab was reviewed internally and was not reviewed by the Drug Benefit Council (DBC) because the CDR recommended not to reimburse dupilumab for moderate-to-severe atopic dermatitis.
Drug Coverage Decision	Non-Benefit
Date	January 22, 2019
Reason(s)	<p>Drug coverage decision is consistent with CDR recommendation.</p> <ul style="list-style-type: none"> Clinical efficacy of dupilumab was assessed in four double-blind, randomized controlled trials (RCTs) that demonstrated improvements in atopic dermatitis severity, symptoms, and quality of life with dupilumab treatment compared with placebo. However, dupilumab has not been compared to any active comparator. There is a lack of data on efficacy and safety for the use of dupilumab in patients where topical prescription therapies are not advisable. Therefore, clinical value of dupilumab treatment and place in therapy is uncertain. At the submitted price, dupilumab was not shown to be cost-effective relative to standard therapy for atopic dermatitis.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit the [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.